Trial Profile
An observational study evaluating asthma control after reduction/withdrawal of Omalizumab in severe asthmatics patients treated for 5 years : real life experience from a Severe Asthma Unit.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Mar 2017
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 22 Mar 2017 New trial record
- 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology